The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
ApexOnco Front Page
Recent articles
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
While Sutro shows why it’s shelved luvelta-T.
The acquisition of Araris follows a 2023 discovery collaboration.
The company buys Belgium’s EsoBiotec for $425m.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
